Trial: 201705069

A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse. CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 914

Phase

III (Cancer Control)

Principal Investigator

Reimers, Melissa

Disease Site

Kidney

Learn more about this study at: clinicaltrials.gov